An open, randomized comparative study of a low-strength frusemide/amiloride combination and bumetanide/potassium chloride in the treatment of mild congestive cardiac failure.
In an open, randomized, parallel group study lasting 8 weeks, nine males and nine females with mild congestive cardiac failure were initially treated daily with 20 mg frusemide/2.5 mg amiloride or 0.5 mg bumetanide/573 mg potassium chloride. In two patients receiving the frusemide combination and in one receiving the bumetanide combination, the daily dose was doubled after 2 weeks' treatment because of inadequate control of symptoms. Mild congestive cardiac failure symptoms (raised jugular venous pressure, oedema and dyspnoea at rest and on effort) were controlled in 9/10 patients receiving frusemide/amiloride but two patients receiving bumetanide/potassium chloride still had mild oedema after 8 weeks. Both treatments were well tolerated overall and there were no clinically significant changes in plasma electrolytes, although one patient treated with frusemide/amiloride was withdrawn due to adverse events.
Rorer Health Care Ltd, Eastbourne, East Sussex, UK.
D
D
Latta
V P
VP
Finnamore
K
K
Dalton
S
S
Allman
D000328:Adult; D000584:Amiloride / Q000627:therapeutic use*; D001794:Blood Pressure; D002034:Bumetanide / Q000627:therapeutic use*; D004232:Diuretics / Q000627:therapeutic use*; D004338:Drug Combinations / Q000627:therapeutic use; D005260:Female; D005665:Furosemide / Q000627:therapeutic use*; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006339:Heart Rate; D006801:Humans; D008297:Male; D011189:Potassium Chloride / Q000627:therapeutic use*; D011795:Surveys and Questionnaires
D004232:Diuretics; D004338:Drug Combinations; D002034:Bumetanide; D011189:Potassium Chloride; D000584:Amiloride; D005665:Furosemide; C046878:frumil